Immune response of Cuban vaccine Soberana 01 not inferior to Soberana 02, experts say

Immune response of Cuban vaccine Soberana 01 not inferior to Soberana 02, experts say
Fecha de publicación: 
3 December 2022
Imagen principal: 

 After concluding the Soberana Centro clinical trial, it was proved that the immune response of Soberana 01 is not inferior to that induced by Soberana 02, an important step for the regulatory entities to authorize its use against COVID-19 or as a booster.

This information was revealed during the closing workshop of the study carried out in the municipalities of Cruces and Palmira, in the province of Cienfuegos(central Cuba), where the research took place in the midst of the great pandemic peak of July and August 2021.

Dr. Julio Damaso Fernandez Aguila, coordinator of these clinical trials in the territory, explained that they evaluated more than 1,400 people, of which they excluded almost 100 because they had been infected with the SARS CoV-2 virus or because they presented decompensated chronic diseases at the time of the study.

He noted that adverse events, mostly mild and localized at the injection site, were more common after the first dose.

Referring to the impact of the administration of the drugs developed by the Finlay Vaccine Institute, Dr. Vicente Verez Bencomo, general director of that center, shared his impressions with the researchers, doctors and volunteers of the study.

He emphasized that the research shows that not only Soberana 02 and Plus are a tremendous combination due to their important incidence in the pediatric population, but also that Soberana 01 is a great vaccine, especially for people over 60 years of age.
This drug is capable of awakening people's innate immunity, he emphasized.

Soberana Centro started on July 26, 2021, after its approval by the Center for State Control of Equipment, Medicines and Medical Devices.

Add new comment

This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Enter the characters shown in the image.